Tamara A. Favorito has served as a director and chair of the audit committee of our Company since August 2021, and as our board chair since May 2023. Ms. Favorito has more than 30 years of life sciences industry experience including 20 years as a chief financial officer. She currently serves as a board member and audit committee chair of Artelo Biosciences, Inc. since March 2021, a publicly-traded clinical-development stage company. Ms. Favorito was interim chief financial officer of Immunic, Inc., a publicly-traded clinical-stage drug development company in 2019. She served as chief financial officer of Signal Genetics, Inc. (now Viridian Therapeutics, Inc.), a publicly-traded molecular diagnostics company, from 2014 to 2017, HemaQuest Pharmaceuticals, Inc., a venture-backed clinical-stage drug development company, from 2010 to 2014 and Favrille, Inc. (now MMR Global, Inc.), a publicly-traded clinical-stage drug development company, from 2001 to 2009. Earlier in her career, she spent eight years in public accounting with Deloitte & Touche LLP and PricewaterhouseCoopers LLP. Ms. Favorito is a certified public accountant (inactive). She received an MBA, emphasis in Finance, from Georgia State University, and a BBA, emphasis in Accounting, from Valdosta State University. Our Board believes that Ms. Favorito’s deep experience in corporate management, finance and life science as chief financial officer of multiple public companies provides her with the qualifications and skills to serve as a director of our Company. Her extensive experience includes leading multiple private and public financings, including Favorille’s IPO, and M&A transactions as well as leading the finance, investor relations, human resources, administration and managed care functions. Ms. Favorito served on the board of directors of Beacon Discovery, Inc. from 2018 until their acquisition in March 2021 and on the board of directors of Kintara Therapeutics, Inc. from 2021 until its merger with TuHura Biosciences, Inc. (NASDAQ: HURA) in October 2024.
What is Tamara A. Favorito's net worth?
The estimated net worth of Tamara A. Favorito is at least $38.55 thousand as of September 12th, 2025. Favorito owns 3,894 shares of Zevra Therapeutics stock worth more than $38,551 as of March 17th. This net worth estimate does not reflect any other investments that Favorito may own. Learn More about Tamara A. Favorito's net worth.
How do I contact Tamara A. Favorito?
Has Tamara A. Favorito been buying or selling shares of Zevra Therapeutics?
Tamara A. Favorito has not been actively trading shares of Zevra Therapeutics over the course of the past ninety days. Most recently, on Friday, September 12th, Tamara A. Favorito bought 3,175 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $7.79 per share, with a total value of $24,733.25. Following the completion of the transaction, the director now directly owns 3,894 shares of the company's stock, valued at $30,334.26. Learn More on Tamara A. Favorito's trading history.
Who are Zevra Therapeutics' active insiders?
Are insiders buying or selling shares of Zevra Therapeutics?
In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 7 times. They sold a total of 133,658 shares worth more than $1,273,867.64. The most recent insider tranaction occured on February, 3rd when SVP Timothy J Sangiovanni sold 3,000 shares worth more than $27,540.00. Insiders at Zevra Therapeutics own 2.4% of the company.
Learn More about insider trades at Zevra Therapeutics. Information on this page was last updated on 2/3/2026.
